

Number	Sex	Age	Diagnosis	Therapy	Duration of IL-1 inhibition (months)	SARS-CoV-2 IgG (OD) Pre-Vaccination	Days after 2nd vaccination	SARS-CoV-2 IgG (OD) post-Vaccination	Neutralizing activity (%)
Patient 1	F	52	AoSD	Canakinumab	17	0,048	47	7.180	17,972
Patient 2	F	22	FMF	Canakinumab	10	0,097	29	9.261	87,237
Patient 3	F	35	sAID	Anakinra	9	0,116	21	8.867	NA
Patient 4	F	30	TRAPS	Canakinumab	4	0,124	10	7.318	96,364
Patient 5	F	27	AoSD	Canakinumab	5	0,1	5	8.908	97,576
Patient 6	M	50	Gout	Canakinumab	4	ND	25	0.732	30,431
Patient 7	F	31	AoSD	Canakinumab	9	0,141	25	7.525	96,219
Patient 8	F	20	FMF	Canakinumab	3	0,127	16	8.592	94,085
Patient 9	M	47	AoSD	Anakinra	17	0,08	12	9.078	96,025
Patient 10	F	17	FMF	Canakinumab	24	0,079	18	8,18	95,297
Control 1	F	50	-	-	-	NA	ND*	2,926	70,642
Control 2	F	37	-	-	-	NA	22	6,640	96,146
Control 3	F	49	-	-	-	NA	47	7,030	95,553
Control 4	F	54	-	-	-	NA	22	7,060	97,152
Control 5	F	43	-	-	-	NA	22	7,330	95,403
Control 6	M	29	-	-	-	NA	27	6,426	97,32
Control 7	F	33	-	-	-	NA	25	7,400	96,902
Control 8	F	53	-	-	-	NA	36	7,480	96,702
Control 9	M	27	-	-	-	NA	21	6,750	97,151
Control 10	F	55	-	-	-	NA	30	7,611	88,483

Table 1: Characteristics of patients and controls. AoSD: Adult onset Still's disease, FMF: familiar Mediterranean fever, sAID: systemic autoinflammatory disease, TRAPS: TNF receptor associated periodic syndrome; ND: not determined (*only first short of vaccine)